patient flow News
-
Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication ...
-
USRM Hires Senior VP of US & International Sales
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Phil Posa has joined its executive management team as Senior Vice President of U.S. & International Sales. Posa, who brings more than 30 years of experience in the pharmaceutical, medical device and regenerative spaces, ...
-
Mozambique: technology revolution hits HIV testing and treatment
Delayed test results often mean HIV patients in Mozambique fail to get timely treatment, but new technology is reducing the need to send tests to far away laboratories, and speeding up test results and HIV treatment. Mozambique's Ministry of Health has increasingly begun experimenting with new technology to make diagnosing and monitoring HIV patients quicker and easier. After a successful 2009 ...
By SciDev.Net
-
Flosonics Medical closes US$14M funding round and expands Board of Directors
The funds will be used to pursue the commercialization of Flosonics Medical’s wireless Doppler ultrasound patch in addition to new product development Flosonics Medical recently announced the close of a $14 million USD funding round led by Arboretum Ventures in partnership with existing investors iGan Partners and Genesys Capital. The Canadian medical device company headquartered in ...
-
enVVeno Medical Announces New U.S. VenoValve Patent
Expanding patent portfolio bolsters protection of the Company’s lead product The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in ...
-
Third Pole Therapeutics Closes $25M Financing - eNOfit Wearable Device Now Ready for Clinical Trials
eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...
-
Revacept - an innovative vascular plaster proved in coronary heart disease
The novel drug Revacept can reduce heart attacks and strokes more efficient and safer than previous standard therapies. This is the result of a study in an investigator initiated study in patients carried out with the German Center for Heart and Circulation Research (DZHK). The study was recently published in JAMA Cardiology. With Revacept severe complications such as heart attacks and stroke in ...
-
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Gesynta Pharma AB today announces that all patients have been recruited for the company's clinical Phase II study with the drug candidate GS-248, which is being evaluated as a treatment for the rare disorder systemic sclerosis.The study is intended to demonstrate proof-of-concept and to evaluate the safety profile of GS-248. Top-line data is expected in the fall of 2022. Systemic ...
-
Zenflow Announces $24 Million Financing Round; Appoints Susan Stimson as President
Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series B financing round. The funding was led by Invus Opportunities and included participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia ...
-
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading ...
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 ...
-
Fonar Announces First Fiscal Quarter Earnings
Total MRI scan volume at the HMCA-managed sites increased 11.6 % to 48,469 scans for the quarter ending September 30, 2021 versus the same quarter one year earlier. This is highest quarterly total in the Company’s history. Diluted Net Income per Common Share increased 53% to $0.55 for the quarter ended September 30, 2021 versus the same quarter one year earlier. Total Revenues-Net ...
-
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at ...
-
Topline results from Phase 3 SPRINTER trial
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
-
Box Hill Hospital Emergency Department Initiates Trial Using FebriDx
Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® POC test to rapidly identify patients presenting with a suspected viral infection consistent with COVID-19. This study is based on ...
-
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting
CorWave, a French medical device company committed to the fight against heart failure, announced that it has successfully completed the first 90-day preclinical study to evaluate its left ventricular assist device (LVAD) operating synchronously with the native heart without the use of sensors. The results were presented at the American Society for Artificial Internal Organs (ASAIO) Annual Meeting ...
By CorWave
-
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has treated the first patient in trial AKST4290-206 (STEEL) studying the effect of AKST4290 on choroidal blood flow (ChBF) in ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
-
Activ Surgical Introduces ActivInsights Augmented Reality Software Suite to Enhance Safety in the Operating Room
BOSTON – June 11, 2021— ActivSurgical™, a digital surgery pioneer, today announced the introduction of ActivInsights™ software suite, a proprietary augmented reality (AR)-based bundle that offers real time tissue assessment in the form of previously unavailable visual overlays. The new software suite, along with the company’s interoperable imaging module, ...
-
Backed by $18 Million and a Nationwide Agreement With One of the Largest Private Hospital Networks in The U.S., ENvizion® Unveils Enteral Feeding Tube ‘GPS’ Tech
ENvizion®, the FDA 510(k) cleared leader in enteral feeding placement navigation technology, announces its agreement with one of the largest private hospital networks in the U.S., with more than one hundred hospitals, to provide ENvizion’s feeding tube placement navigation devices nationwide. The company’s endeavor is backed by $18 million in investment. Key investors include ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you